Diagnostic Center | December 10, 2024
Ichnos Glenmark Innovation presents first clinical data from Phase 1 study of Trispecific TREAT antibody
Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma